Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still ’s Disease in the U.S. Real-World Settings
ConclusionsIn US clinical practice, physician perceived/experienced efficacy/effectiveness of canakinumab and lack-of-response to previous treatment were the primary reasons for canakinumab initiation among patients with SJIA/AOSD. Physician perceived/experienced efficacy/effectiveness and convenient administration/dosing of canakinumab were the most common reasons for canakinumab initiation among children, whereas lack-of-response to previous treatment and ability to discontinue/spare steroids being the most frequent reasons among adults.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Allergy & Immunology | Arthritis | Children | Dermatology | Enbrel | Humira | Pediatrics | Rheumatology | Skin | Study